Interestingly, agmatine, a metabolite produced by the gut bacterium Bacteroides vulgatus was shown to impair ovarian function by inhibiting GLP-1 secretion through activation of the farnesoid X receptor (FXR) (Yun et al., 2024)
Since retatrutide is investigational and not approved, the practical alternatives are approved GLP-1 pathway options: semaglutide as Ozempic, Wegovy, and Rybelsus, tirzepatide as Mounjaro and Zepbound, and liraglutide as Saxenda and Victoza
Of note, GLP-1 improvement of cardiovascular performance is, at least in part, independent of its ability to decrease body weight and to improve lipid metabolism, and GLP-1 may promote its cardiac effects via direct action at GLP-1R as well as indirect mechanisms independent of cardiac GLP-1R action [201,611,622]
Lewis D